Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 148-154

  Van De Vaart, P J M ^a   Van Der Vange, N ^a   Zoetmulder, F A N ^a   Van Goethem, A R ^a   Van Tellingen, O ^a   Ten Bokkel Huinink, W W ^a   Beijnen, J H ^a   Bartelink, H ^a   Begg, A C ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Cisplatin DNA adducts; Hyperthermia; Intraperitoneal; Penetration depth; Pharmacokinetics

Indexed keywords

CISPLATIN; DNA;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DNA ADDUCT; DRUG MECHANISM; DRUG PENETRATION; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IMMUNOCYTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DNA ADDUCTS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031935699     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00370-5     Document Type: Article

References (35)

1. McClay EF, Howell SB, A review: intraperitoneal cisplatin in the management of patients with ovarian cancer, [review]. Gynec Oncol 1990, 36(1), 1-6.
2. Neijt JP, ten Bokkel Huinink WW, van der Burg ME. Long-term survival in ovarian cancer: mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991, 27, 136-172.
3. Longo DL, Young RC. The natural history and treatment of ovarian cancer. Ann Rev Med 1981, 32, 475-490.
4. Markman M. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer, [review]. Semin Oncol 1994, 21 (2 Suppl. 2), 17-19.
5. Howell SB, Zimm S, Markman M, el al. Long-term survival of advanced refraction ovarian carcinoma patients with smallvolume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987, 5(10), 1607-1612.
6. Howell SB, Kirmani S, McClay EF, Kirn S, Braly P, Plaxe S. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Semin Oncol 1991, 18(1 Suppl. 3), 5-10.
7. Alberts DS, Liu PY, Hannigan EV, et al Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (PvO cyclophosphamide (CPA) in patients with optimal disease stage III ovarian cancer: A AWOG-GOG-ECOG intergroup study. [Abstract]. ProcASCO 1995, 14, 273.
8. Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990, 26, 755-762.
9. Markman M, Reichman B, Hakes T, et al. Responses to secondline cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991, 9(10), 1801-1805.
10. Arancia G, Crateri trovalusci P, Mariutii G, Mondovi B. Ultrastructural changes induced by hyperthermia in Chinese hamster V79 fibre-blasts. Int J Hyperthermia 1989, 5, 341-350.
11. Hahn GM, Shiu EC. Effect of pH and e levated temperatures on the cytotoxicity of some therapeutic agents on Chinese hamster cells in vitro. Cancer Res 1983, 43, 5789-5791.
12. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-13° C) and adriamycin (or bleomycin) in mammalian cell inactivation. PNAS 1975, 172, 937-940.
13. Hettinga JVE, Lemstra W, Koning AVCT, Kampinga HH. Cisplatin sensitivity and thermochemosensitization in thermotolerent cDDP-sensitive and -resistant cell lines. Br J Cancer 1995, 71, 498-504.
14. Ohno S, Siddik ZH, Zwelling LA, Bull |MC. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequenceing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chtmother Pharmacol 1994, 34, 302-306.
15. Akaboshi M, Tanaka Y, Kawai K, Akuta K, Imasunaga S, Ryu J. Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with Pt:-195m-radiolabelled cisdiaminedichloroplatinum(II). Int J Radiat Biol 1994, 66, 215-220.
16. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 19')4, 69(2), 235-241.
17. Los G, van Vugt MJ, Den Engelse L. Pinedo HM. Effects of temperature on the interaction of cispliitin and carboplatin with cellular DNA. Biochem Pharmacol 1993, 46(7), 1229-1237.
18. Fichtinger-Schepman AMJ, Van Oosterom AT, Lohman PHM, Berends F. cis-Diamminedichloroplai:inum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res 1987, 47, 3000-4004.
19. Reed E, Gupta-burt S, Litterst CL, Poirier MC. Characterization of DNA damage recognized by an antiserum elicited against cis-diamminocLloroplatinum(II)-modified DNA. Carcinogenesis 1990, 11,2117-2121.
20. Terheggen PMAB, Emondt JY, Floot I!GJ, et al. The correlation between cell killing by ds-diammmedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res 1990, SO, 3556-3561.
21. Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH. Validated method for the determination of carboplatin in biological fluids by Zeeman Atomic Absorption Spectrometry. Fresenius J Anal Ghent 1995, 3S1, 1820-1824.
22. Terheggen PMAB, Floot BGJ, Lempers ELM, van Tellingen O, Begg AC, Den Engelse L. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemother Pharmacol 1991, 28(3), 185-191.
23. Los G, Mustsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, Me Vie JG. Direct diffusion of cts-diamminedichloroplatinum(ll) in intraperitoneal tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989, 49, 3380-3384.
24. Los G, Mutsaers PH, Dubbelman R, van der Hoeven CJ, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991, 28, 159-165.
25. Los G, Sminia P, Wondergem J, Mutsaers PH, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. EurJ Cancer 1991, 27(4), 472-477.
26. Nishiue T, Kojima O. Local treatment of rabbit VX2 rectal carcinoma with combined hyperthermia and intratumoral CDDP injection. Int J Hyperthermia 1994, 10, 619-626.
27. Blommaert FA, Michael C, Terheggen PMAB, et al. Druginduced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 1993, S3, 5669-5675.
28. Reed E, Parker RJ, Gill I, et al. Platinum-DNA adduct in leukocyte of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 1993, S3, 3694-3699.
29. Los G, Blommaert FA, Barton R, et al. Selective infra-arterial infusion of high dose platin in advanced head and neck cancer patients results in high tumor platinum concentrations and platin-DNA adduct formation. Cancer Chemother Pharmacol 1995,37 (2), 150-154.
30. Selby P, Buick RN, Tannack I. A critical appraisal of the human tumor stem-cell assay. New EnglJ Med 1983, 308, 129-134.
31. Von Hoff DD, Clark GM, Stogdill J et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983, 43, 1926-1931.
32. Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr. IP cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 1983, 67(3), 235238.
33. Pretorius RG, Hacker NE, Berek JS, et al. Pharmacokinetics of IP cisplatin in refractory ovarium carcinoma. Cancer Chemother Pharmacol 1983, 67(12), 1085-1092.
34. Zakris L, Dewhirst MW, Hoopes PJ, Page RL, Olshen JR. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 1987, 5(10), 1613-1620.
35. Howell SB, Pfeifle CE, Wung WE, Olshen A. Intraperitoneal cisdiamminechloroplatinum with systemic thiosulfate protection. Cancer Res 1983, 43, 1426-1431.